Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPM Regimen for Symptomatic LGLL
NCT04453345Phase 3Unknown
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- May 2013
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of thalidomide in large granular lymphocytic leukemia (LGLL), sponsored by Institute of Hematology and Blood Diseases Hospital. Status: unknown.
02
Drugs
thalidomide
03
Conditions
large granular lymphocytic leukemia (LGLL)
Beyond the preview
Go deeper on NCT04453345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04453345.